Antibody responses against SARS-coronavirus and its nucleocaspid in SARS patients - PubMed (original) (raw)
Antibody responses against SARS-coronavirus and its nucleocaspid in SARS patients
Yulin Shi et al. J Clin Virol. 2004 Sep.
Abstract
Background: SARS-Cov is the etiologic agent of severe acute respiratory syndrome. An understanding of the antibody responses to the viral components is very important for diagnosis and vaccine development.
Objective: The spectrum of SARS-specific antibody profiles in SARS patients was investigated from 7 to 210 days after the onset of the symptoms.
Study design: Serial serum samples from 14 SARS patients were isolated from 7 to 210 days after the onset of the symptoms, and were tested for anti-viral IgG and IgM by indirect immunofluorescence tests (IFA), anti-nucleocaspid antibody by ELISA tests and viral neutralization.
Results: Anti-viral (IgG) and anti-nucleocaspid antibodies were observed in 13 of 14 patients at 14 days after the onset of symptoms, and in all 14 patients at 30-210 days thereafter. Anti-viral antibody (IgM) was detected maximally at 30 days, later than that for the IgG class. IgM antibody declined and became undetectable between 60 to 180 days after the onset of the symptoms. Neutralizing viral antibodies were demonstrated in the sera from all of the patients with SARS symptoms.
Conclusions: Anti-viral IgG, IgM, and anti-nucleocaspid antibodies were detected 7-30 days in patients after the onset of SARS symptoms. Anti-viral IgM antibodies disappeared earlier than IgG. Viral neutralization was demonstrated in the sera from the convalescent patients.
Figures
Fig. 1
Geometric means of immunofluorescent antibody titers for IgG (□) and IgM (○) and anti-nucleocaspid antibody titres (×) in 14 probable SARS patients. The error bars correspond to 1 S.D. Sera were collected from 7 to 210 days after the onset of the symptoms. Anti-viral IgG and IgM are detected by IFA and anti-NP total Ig by antigen-capture ELISA.
Similar articles
- Longitudinal profile of immunoglobulin G (IgG), IgM, and IgA antibodies against the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in patients with pneumonia due to the SARS coronavirus.
Woo PC, Lau SK, Wong BH, Chan KH, Chu CM, Tsoi HW, Huang Y, Peiris JS, Yuen KY. Woo PC, et al. Clin Diagn Lab Immunol. 2004 Jul;11(4):665-8. doi: 10.1128/CDLI.11.4.665-668.2004. Clin Diagn Lab Immunol. 2004. PMID: 15242938 Free PMC article. - [A follow up study of total IgM, IgG, nucleoprotein and spike protein antibodies against severe acute respiratory syndrome (SARS) coronavirus in patients with SARS].
Yan HP, Tan YF, Zhuang H, Zhou YS, Zhao CH, Feng X, Jin RH, Wu H, Fu Y. Yan HP, et al. Zhonghua Nei Ke Za Zhi. 2006 Nov;45(11):896-9. Zhonghua Nei Ke Za Zhi. 2006. PMID: 17313874 Chinese. - [Study on the changing regularity of special antibody and expression of stomach and enteric involvement on SARS-coronavirus infection in the recovery period of severe acute respiratory syndrome].
Shi YL, Li LH, Sun ZH, Chen JY, Liao Y, Zeng LL, Zhang W, Chen XD, Cao C. Shi YL, et al. Zhonghua Liu Xing Bing Xue Za Zhi. 2010 Jul;31(7):795-9. Zhonghua Liu Xing Bing Xue Za Zhi. 2010. PMID: 21162846 Chinese. - Severe acute respiratory syndrome (SARS): development of diagnostics and antivirals.
Sørensen MD, Sørensen B, Gonzalez-Dosal R, Melchjorsen CJ, Weibel J, Wang J, Jun CW, Huanming Y, Kristensen P. Sørensen MD, et al. Ann N Y Acad Sci. 2006 May;1067(1):500-5. doi: 10.1196/annals.1354.072. Ann N Y Acad Sci. 2006. PMID: 16804033 Free PMC article. Review.
Cited by
- Assessment of humoral immune response to two mRNA SARS-CoV-2 vaccines (Moderna and Pfizer) in healthcare workers fully vaccinated with and without a history of previous infection.
Serrano L, Algarate S, Herrero-Cortina B, Bueno J, González-Barriga MT, Ducons M, Montero-Marco J, Acha B, Taboada A, Sanz-Burillo P, Yuste C, Benito R; RIPOVAC Study Group. Serrano L, et al. J Appl Microbiol. 2022 Sep;133(3):1969-1974. doi: 10.1111/jam.15699. Epub 2022 Jul 18. J Appl Microbiol. 2022. PMID: 35801660 Free PMC article. - Multiepitope Proteins for the Differential Detection of IgG Antibodies against RBD of the Spike Protein and Non-RBD Regions of SARS-CoV-2.
Gomes LR, Durans AM, Napoleão-Pêgo P, Waterman JA, Freitas MS, De Sá NBR, Pereira LV, Furtado JS, Aquino RG, Machado MCR, Fintelman-Rodrigues N, Souza TML, Morel CM, Provance DW, De-Simone SG. Gomes LR, et al. Vaccines (Basel). 2021 Sep 3;9(9):986. doi: 10.3390/vaccines9090986. Vaccines (Basel). 2021. PMID: 34579223 Free PMC article. - Immunological assessment of SARS-CoV-2 infection in pregnancy from diagnosis to delivery: A multicentre prospective study.
Glennon K, Donnelly J, Knowles S, McAuliffe FM, O'Reilly A, Corcoran S, Walsh J, McMorrow R, Higgins T, Bolger L, Clinton S, O'Riordan S, Start A, Roche D, Bartels H, Malone C, McAuley K, McDermott A, Inzitari R, O'Donnell CPF, Malone F, Higgins S, De Gascun C, Doran P, Brennan DJ. Glennon K, et al. PLoS One. 2021 Sep 20;16(9):e0253090. doi: 10.1371/journal.pone.0253090. eCollection 2021. PLoS One. 2021. PMID: 34543278 Free PMC article. - Specific COVID-19 Symptoms Correlate with High Antibody Levels against SARS-CoV-2.
Amjadi MF, O'Connell SE, Armbrust T, Mergaert AM, Narpala SR, Halfmann PJ, Bashar SJ, Glover CR, Heffron AS, Taylor A, Flach B, O'Connor DH, Kawaoka Y, McDermott AB, Sethi AK, Shelef MA. Amjadi MF, et al. Immunohorizons. 2021 Jun 17;5(6):466-476. doi: 10.4049/immunohorizons.2100022. Immunohorizons. 2021. PMID: 34398806 Free PMC article. - On the road to ending the COVID-19 pandemic: Are we there yet?
Case JB, Winkler ES, Errico JM, Diamond MS. Case JB, et al. Virology. 2021 May;557:70-85. doi: 10.1016/j.virol.2021.02.003. Epub 2021 Feb 26. Virology. 2021. PMID: 33676349 Free PMC article. Review.
References
- Chen W, Xu Z, Mu J. Antibody response and viraemia during the course of severe acute respiratory syndrome (SARS)-associated coronavirus infection. J. Med. Microbiol. 2004;53:435–438. - PubMed
- Drosten C, Günther S, Preiser W. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 2003;348:1967–1976. - PubMed
- Marra M.A, Jones S.J, Astell C.R. The genome sequence of the SARS-associated coronavirus. Science. 2003;300:1399–1404. - PubMed
- Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt G.M, Ahuja A, Yang M.Y, Leung C.B, To K.K, Lui S.F, Szeto C.C, Chung S, Jung J.J. A major outbreak of severe acute respiratory syndrome in Hong Kong. N. Engl. J. Med. 2003;348:1986–1994. - PubMed
- Li G, Chen X, Xu A. Profile of specific antibodies to the SARS-associated coronavirus. N. Engl. J. Med. 2003;349:508–509. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous